http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010507361-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2007-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010507361-A |
| titleOfInvention | Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant |
| abstract | The present invention relates to a nucleic acid represented by the general formula (I): G 1 X m G n or the general formula (II): C 1 X m C n, which may be modified with a lipid. The nucleic acids of the present invention act as immunostimulants that induce innate immune responses. The present invention also includes an immunostimulatory agent of the present invention in combination with a pharmaceutically active carrier / vehicle (and optionally further combined with auxiliary substances, additives and / or other adjuvants), respectively. The pharmaceutical composition containing it (1st Embodiment). In another embodiment, the nucleic acids of the invention are combined with at least one pharmaceutically active ingredient, pharmaceutically acceptable carrier / vehicle (and in some cases, auxiliary substances, additives and / or other Further combined with an adjuvant). Therefore, the present invention is directed to a vaccine corresponding to the pharmaceutical composition of the present invention (second embodiment). A pharmaceutically active ingredient (for example, an antigen) induces a specific immune response. The invention further relates to the use of the nucleic acid of the invention or the pharmaceutical composition of the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014531396-A |
| priorityDate | 2006-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1508.